CJC-1295 vs Ipamorelin: Two Pathways to One Pulse

What the research says about CJC-1295

CJC-1295, in its DAC-bearing form, is a growth-hormone-releasing-hormone (GHRH) analogue built to bind the pituitary GHRH receptor and stretch the exposure window well past native GHRH's few-minute half-life [1]. The DAC portion binds serum albumin, and that binding is what pushes the peptide's presence in circulation out to a multi-day window in human studies [1][3].

Two published human studies, both in healthy adults, form the core evidence base for the DAC form. Teichman et al. (2006) reported prolonged growth hormone and IGF-1 elevation after DAC-form dosing, and a companion study by Ionescu and Frohman (2006) found that the elevation preserved the body's normal pulsatile GH release pattern rather than flattening it into a constant plateau [3]. A related human study found shifts in the serum protein profile after a single DAC-form dose, though that work was exploratory biomarker research rather than a clinical outcomes trial [6].

The no-DAC analogue, usually called Modified GRF(1-29), behaves like a different molecule from a pharmacokinetic standpoint. No dedicated published clinical trial for the no-DAC form turned up in the current literature, even though it shows up more often than the DAC form in community and commercial protocol discussions [2]. Animal work, including a rat study showing roughly a four-fold increase in GH exposure and a GHRH-knockout mouse model showing restored growth with daily dosing, supports the GHRH mechanism generally but does not stand in for human no-DAC data [1].

One early human program, studying the DAC form for HIV-associated visceral fat, was halted after a participant death before efficacy results were published [3]. That outcome is part of the compound's public record, and it is worth knowing regardless of which form of CJC-1295 is under discussion.

What the research says about ipamorelin

Ipamorelin is a synthetic pentapeptide that acts on the growth hormone secretagogue receptor (GHS-R1a), the same receptor ghrelin binds naturally [4]. It was developed at Novo Nordisk in the 1990s by trimming a longer secretagogue sequence down to five amino acids while keeping GH-releasing activity intact [4].

The defining feature in the literature is selectivity. In a conscious swine model, ipamorelin raised growth hormone without raising cortisol or ACTH, even at doses far above its effective GH dose, while two related secretagogues tested in the same study raised both stress hormones [4]. A human dose-escalation study later confirmed the same cortisol-and-ACTH-sparing pattern [5].

The human data set is small but real: one Phase I dose-escalation study in 40 healthy men established the pharmacokinetic profile, and two Phase II trials tested ipamorelin for postoperative bowel recovery after abdominal surgery [5][7]. Neither Phase II trial reached statistical significance on its primary endpoint against placebo, and no Phase III trial for ipamorelin has ever been conducted [7]. Beyond that clinical program, animal studies have looked at bone formation, body composition, and GI motility, with a rat study reporting increased bone formation rate when ipamorelin was combined with a glucocorticoid known to suppress bone growth [4].

Why they are studied together

CJC-1295 and ipamorelin act on two separate receptors that both converge on the same pituitary cells that release growth hormone. CJC-1295 signals through the GHRH receptor; ipamorelin signals through the ghrelin receptor [1][4]. Because the two pathways are independent rather than overlapping, earlier literature on combining a GHRH analogue with a secretagogue generally reported a larger combined growth hormone pulse than either compound produced alone, though the effect has not been reproduced in every study, and no dedicated clinical trial of the CJC-1295-plus-ipamorelin combination specifically has been published [1][4].

That mechanism, not marketing convenience, is why research suppliers commonly list the pairing as a set: a short-acting GHRH signal from CJC-1295 no DAC, paired with a clean, receptor-selective pulse from ipamorelin. See the CJC-1295 no DAC and Ipamorelin set for how Curo lists the pairing, or the CJC-1295 no DAC and ipamorelin single-vial listings on their own.

Vs. tesamorelin and vs. sermorelin

Both CJC-1295 and ipamorelin are frequently searched alongside two other GHRH-pathway peptides. Tesamorelin is also a GHRH analogue, like CJC-1295, but it holds a distinct regulatory position: it is the one compound in this group with an FDA-approved drug label, cleared for HIV-associated lipodystrophy under the brand name Egrifta, which means its human safety and efficacy record rests on a formal approval pathway rather than early-phase trials alone [12]. Sermorelin is a shorter GHRH fragment, GHRH(1-29), and unlike CJC-1295's DAC-bound design, it carries no albumin-binding modification, giving it a short, native-length half-life closer to endogenous GHRH than to CJC-1295's extended-exposure DAC form [1]. Both comparisons come up because all four compounds share the GHRH-or-secretagogue mechanism class, not because they are interchangeable; each has its own PK profile, trial record, and regulatory status.

What a COA shows for a blend vial vs. single vials

A certificate of analysis documents identity and purity for what is actually in a vial, tested by lot. For a single-compound vial, such as CJC-1295 no DAC alone or ipamorelin alone, the COA should show one peptide's identity confirmation and purity percentage tied to that specific lot number.

A blended or "stack" vial, when a supplier pre-mixes two peptides into one vial, needs a COA that accounts for both compounds independently: identity and purity for each peptide, not a single combined purity figure. Curo lists CJC-1295 no DAC and ipamorelin as two separate single-compound vials shipped together as a set rather than pre-mixed, which is the more verifiable structure, since each vial carries its own lot-specific documentation. Readers evaluating any supplier's blend product should ask whether the COA shown covers each peptide by lot or only a general product-level claim. The COA lookup page shows how lot-specific documentation is structured.

Regulatory status

United States (FDA). Neither CJC-1295 nor ipamorelin is FDA-approved for any human indication, and no new drug application has been submitted for either [8][10]. Both were nominated for FDA's interim 503A compounding bulks list, which governs which bulk substances licensed compounding pharmacies may use. In September 2024, ipamorelin acetate was removed from the interim Category 2 (restricted) list after its nominators withdrew, but on October 29, 2024, the Pharmacy Compounding Advisory Committee reviewed ipamorelin for formal inclusion on the 503A bulks list and voted against it, citing limited human data and impurity-characterization gaps [10]. CJC-1295 was similarly rejected for 503A bulks list inclusion at a PCAC meeting in December 2024 [9].

In February 2026, the Department of Health and Human Services said a group of peptides, including CJC-1295 and ipamorelin, might move back to the less-restricted Category 1 compounding status [13]. No formal FDA rule change implementing that reversal has published as of this regulatory refresh, dated 2026-09-08. Industry coverage describes the policy direction as set and the formal rulemaking as still in progress [13][14].

WADA. Both compounds fall under Section S2 of the World Anti-Doping Agency's 2026 Prohibited List, "Peptide hormones, growth factors, related substances, and mimetics," which is prohibited at all times in and out of competition for athletes under the WADA Code [15]. CJC-1295, as a GHRH analogue, and ipamorelin, as a growth hormone secretagogue, both fall within that section's growth-hormone-releasing-factor and secretagogue categories.

Sources

[1] Jetté L, et al. "Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor... identification of CJC-1295 as a long-lasting GRF analog." Endocrinology, 2005. https://doi.org/10.1210/en.2004-1286

[2] National Center for Biotechnology Information. "CJC1295 Without DAC." PubChem CID 91976842. https://pubchem.ncbi.nlm.nih.gov/compound/91976842

[3] Teichman SL, et al. "Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295... in healthy adults." J Clin Endocrinol Metab, 2006. https://doi.org/10.1210/jc.2005-1536

[4] Raun K, et al. "Ipamorelin, the first selective growth hormone secretagogue." Eur J Endocrinol, 1998;139:552-561. https://doi.org/10.1530/eje.0.1390552

[5] Gobburu JVS, et al. "Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers." Pharm Res, 1999;16:1412-1416. https://doi.org/10.1023/A:1018955126402

[6] Sackmann-Sala L, et al. "Activation of the GH/IGF-1 axis by CJC-1295... results in serum protein profile changes in normal adult subjects." Growth Horm IGF Res, 2009. https://doi.org/10.1016/j.ghir.2009.03.001

[7] Beck DE, et al. Ipamorelin Phase II postoperative ileus trial. Int J Colorectal Dis, 2014; ClinicalTrials.gov NCT00672074. https://clinicaltrials.gov/study/NCT00672074

[8] U.S. Food and Drug Administration. Bulk drug substances used in compounding under section 503A, CJC-1295 nomination status. https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act

[9] Alliance for Natural Health USA. "FDA Strikes Another Blow Against Compounded Medicines: Peptides Rejected at Latest PCAC Meeting." December 6, 2024.

[10] U.S. Food and Drug Administration / Pharmacy Compounding Advisory Committee. Ipamorelin 503A bulks list review, October 29, 2024. https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act

[11] World Anti-Doping Agency. "2026 Prohibited List - International Standard," effective January 1, 2026. https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf

[12] U.S. Food and Drug Administration. Drugs@FDA record for Egrifta (tesamorelin for injection), NDA 022505. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022505

[13] Chammout M. "The Peptide Reclassification Everyone's Talking About: A Pharmacist's Take on What RFK Jr's Announcement Actually Means." Pharmacy Times, June 4, 2026. https://www.pharmacytimes.com/view/the-peptide-reclassification-everyone-s-talking-about-a-pharmacist-s-take-on-what-rfk-jr-s-announcement-actually-means

[14] Frier Levitt Attorneys at Law. "FDA Peptide Regulation: RFK Announcement and Compounding Pharmacies." 2026.

[15] World Anti-Doping Agency. "2026 Prohibited List - International Standard," Section S2, effective January 1, 2026. https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf

Further reading on Curo: the single-compound profiles for CJC-1295, with and without DAC and ipamorelin's completed trials, plus the Wolverine Stack, BPC-157 and TB-500 explained, BPC-157 vs TB-500: differences and when to combine, and Semax vs Selank: differences.

For more on how Curo verifies its lots, see our quality and testing standard and how to verify a certificate of analysis. This is research-use information only; see the Research Use Only policy.

FAQ

Is CJC-1295 the same thing as ipamorelin?

No. They are two different peptides that act on two different receptors. CJC-1295 is a GHRH analogue; ipamorelin is a selective ghrelin-receptor agonist. They are often studied together, not because they are the same compound, but because their mechanisms are independent of each other [1][4].

Does "CJC-1295" always mean the DAC form?

In the strict sense, yes. CJC-1295 properly refers to the DAC-bearing, long-acting molecule. The no-DAC analogue, Modified GRF(1-29), is a related but distinct short-acting peptide, and the literature keeps the two forms separate because their pharmacokinetics differ substantially [1][2].

Is either compound FDA-approved?

No. Neither CJC-1295 nor ipamorelin has FDA approval for any indication, and both were reviewed and rejected for the FDA's 503A compounding bulks list in 2024 [9][10]. Tesamorelin, a related GHRH analogue, is the one compound in this comparison group that does carry FDA approval, for a specific indication [12].